Treatment group:Ixazomib

2 trials

Sponsors

The Second Hospital of Hebei Medical University, Qingdao Municipal Hospital

Conditions

multiple myeloma

Phase 4

Efficacy and safety of IVPD regimen in patients with relapsed/refractory multiple myeloma resistant to bortezomib and/or lenalidomide: a multicenter, single-arm, prospective clinical study

RecruitingChiCTR2300078643

The Second Hospital of Hebei Medical Universitymultiple myeloma

Start: 2023-12-20Updated: 2023-12-19

An open and exploratory clinical trial of ixazomib combined with melphalan/prednisone (IMP) in the treatment of elderly patients with multiple myeloma

Active, not recruitingChiCTR2400084725

Qingdao Municipal Hospitalmultiple myeloma

Start: 2024-05-31Updated: 2024-05-27